Ligand Pharmaceuticals (NASDAQ:LGND) reported first-quarter 2026 results that management said reflect the operating leverage of its royalty aggregation strategy, highlighted by growing royalties from ...
Investor's Business Daily on MSN
Why these four biotech stocks prove that follow-on entries still pop up in stock market leaders
AnaptysBio recorded $234 million in sales over the past four quarters.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results